Scholar Rock reported its first commercial results for the third quarter of 2026 following the FDA approval of ISEMBYLD for spinal muscular atrophy. The company beat both top and bottom-line analyst estimates while securing a significant non-dilutive cash infusion through the sale of a regulatory asset.
Key Highlights
- Net product revenue reached $0.57 million, exceeding the $0.30 million estimate due to initial shipments following the September 11 FDA approval.
- The company strengthened its balance sheet by entering into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $205 million in cash.
- Third quarter net loss of $0.81 per share outperformed the consensus expectation of a $0.85 loss per share.
- Regulatory progress continues globally with the Japanese JNDA accepted under priority review and an expected European CHMP opinion in the first half of 2027.